All In Biotech

Drug Trial Radar · NCT05785754

DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

Last checked: Nov 20, 2026Latest source record: Jun 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

320

Planned (sponsor's estimate)

Start

Jun 28, 2023

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
DynamiCure BiotechnologyIndustry
Sponsor type
Industry
First posted
Mar 27, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label, Phase 1 study to assess the effects of DCSZ11 as a monotherapy and in combination in patients with advanced or metastatic solid tumors. The study consists of an Escalation Phase (Phase 1a) and a Dose Expansion/Optimization Phase (Phase 1b).

Conditions

  • Advanced or Metastatic Solid Tumors

Interventions

  • DCSZ11Drug

    A monoclonal antibody that binds to CD93, DCSZ11 will be administered as a single intravenous (IV) infusion on Day 1 in each 21-day cycle.

  • PembrolizumabDrug

    Pembrolizumab injection

  • DoxorubicinDrug

    1b SOC Cohort 1: Doxorubicin combination in soft tissue sarcoma

  • TebentafuspDrug

    1b SOC Cohort 2: Tebentafusp combination in uveal melanoma

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1a: Incidence of dose limiting toxicites (DLTs)Time frame: 21 days
  2. Phase 1a: Frequency and severity of treatment emergent adverse eventsTime frame: up to 3 years
  3. Phase 1b: Overall response rate (ORR) per Investigator-assessed Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST)Time frame: 1 year

Locations

35 sites in 4 countries. Site status is shown where the registry gives one.

  • University of Alabama

    Birmingham, Alabama · Recruiting

  • Mayo Clinic

    Phoenix, Arizona · Recruiting

  • HonorHealth

    Scottsdale, Arizona · Recruiting

  • University of Colorado

    Aurora, Colorado · Recruiting

  • Sarah Cannon Research Institute Denver Healthone

    Denver, Colorado · Recruiting

  • Yale Cancer Center

    New Haven, Connecticut · Recruiting

  • Mayo Clinic

    Jacksonville, Florida · Recruiting

  • University of Miami

    Miami, Florida · Recruiting

  • John Hopkins Sidney Kimmel Comprehensive Cancer Center

    Baltimore, Maryland · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Completed

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

  • MonteFiore

    The Bronx, New York · Recruiting

  • Ohio State University

    Columbus, Ohio · Recruiting

  • SCRI Oncology Partners

    Nashville, Tennessee · Recruiting

  • Townsville Hospital

    Douglas, Australia · Recruiting

  • Liverpool Hospital

    Liverpool, Australia · Completed

  • Mater Misericordiae Health Services Brisbane Ltd

    South Brisbane, Australia · Recruiting

  • Sydney Adventist Hospital

    Wahroonga, Australia · Withdrawn

  • Scientia Clinical Research

    Randwick, New South Wales, Australia · Recruiting

  • St Vincent's Hospital

    Sydney, New South Wales, Australia · Recruiting

  • University of Sunshine Coast

    Buderim, Queensland, Australia · Withdrawn

  • Southern Oncology Clinical Research Unit (SOCRU)

    Bedford Park, South Australia, Australia · Recruiting

  • The Queen Elizabeth Hospital (TQEH)

    Woodville South, South Australia, Australia · Recruiting

  • Monash Health

    Clayton, Victoria, Australia · Recruiting

  • Cabrini Hospital

    Malvern, Victoria, Australia · Completed

  • Linear Clinical Research Limited

    Nedlands, Western Australia, Australia · Recruiting

  • Inje University Haeundae Paik Hospital

    Busan, South Korea · Recruiting

  • Dong-a University Hospital

    Busan, South Korea · Recruiting

  • Cha University Bundang Medical Center

    Gyeonggi-do, South Korea · Recruiting

  • Severance Hospital, Yonsei University Health System

    Seoul, South Korea · Recruiting

  • Asan Medical Center

    Seoul, South Korea · Withdrawn

  • Kaohsiung Medical University Chung-ho Memorial Hospital

    Kaohsiung City, Taiwan · Recruiting

  • National Cheng Kung University Hospital

    Tainan, Taiwan · Recruiting

  • Taipei Veterans General Hospital

    Taipei, Taiwan · Recruiting

  • National Taiwan University Hospital

    Taipei, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.